Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 7, 2011

Dalton to Provide Aseptic Fill/Finish Services to AdeTherapeutics

  • Dalton Pharma Services and AdeTherapeutics (ADE) have entered into a clinical manufacturing services agreement to develop therapeutic options in inflammation and acute care medicine. Dalton will provide aseptic fill/finish services under cGMP for ADE's sterile antiadhesion (scar tissue reduction) product.

    Dalton’s aseptic manufacturing facility maintains a static and operations Grade A (ISO Class 5) environment. All areas of its aseptic processing facility, including ancillary support areas, are routinely monitored for viable airborne contamination, viable contamination on surfaces, and non-viable airborne contamination by the firm's QC microbiology laboratory. The area is also supported by the company’s analytical chemistry laboratory and quality assurance department.

    ADE’s surgery adhesion prevention product is a protein designed to reduce adhesions or scar tissue caused by surgeries. The therapeutic has shown promise for other large medical need areas such as hernias and surgical site infections leading to sepsis, joint surgeries, and surface scars, according to the company.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »